logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
24/10/2026
Couche-Tard's acquisition offer values Cumberland Farms at up to $8 billion.
Latest
21 m ago
Study data presented at a medical conference on Saturday showed that Amgen's drug Imdelltra, when used in combination with AstraZeneca's immunotherapy Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, outperforming Imfinzi alone. For this aggressive and difficult-to-treat cancer, Imfinzi is currently the standard post-chemotherapy treatment option for patients whose disease has not worsened after initial chemotherapy. The study showed that patients in the combination group had a median survival of 21.1 months, compared with 12.7 months in the monotherapy group. Amgen Chief Medical Officer Paul Burton said that the earlier Imdelltra is used, the greater the clinical benefit patients receive. He said the results are unprecedented in advancing the treatment of extensive-stage small cell lung cancer.
24 m ago
Amgen drug combined with immunotherapy extended patient survival in lung cancer clinical trial.
27 m ago
Navigational warning: Rocket launch in certain waters of the South China Sea, entry prohibited
30 m ago
Bitcoin falls below $80,000, down 1.54% intraday.
36 m ago
SanDisk falls over 5% in the grey market, now at $1,224.465.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.